Lupus Canada Launches Research Funding Program

Program Overview

The Lupus Canada Catalyst Grant Program was launched to support high calibre start-up projects that have the potential to significantly advance the field or impact the lives of persons living with lupus and their families. This grant provides support to investigators to initiate new research ideas and projects and is intended to complement rather than compete with traditional sources of funding such as the Canadian Institutes for Health Research (CIHR). Our hope is that investigators who receive an LC grant will have greater success in obtaining larger multiyear grants from traditional funders.

Important Dates

Funding Opportunity Launch March 2017
Registration Deadline June 2, 2017
Application Deadline July 4, 2017
Anticipated Notice of Decision September 30, 2017
Funding Start Date January 1, 2017

How to Apply

Interested investigators should review the full program description and eligibility requirements in our Funding Opportunity Announcement (below).

 

Important Documents

Past Competitions

Competition Application Metrics Funded Projects
Catalyst Grant 2016 2/6 Applications Funded

 

$35,000 Awarded

Principal Investigator: Dr. Murray B. Urowitz

 

Institution: University Health Network, Krembil Research Institute

Project Title: Scrutinizing the Heterogeneity of Systemic Lupus Erythematosus: Defining Phenotypes

Project Lay Summary: 

Lupus is a disease that mimics multiple diseases. The focus of this project is to phenotype patients, meaning to determine how clinically different lupus patients are from one another and how or why these differences exist. Lupus is characterised by unpredictable relapses and remissions in the majority of patients. However, in small proportion, lupus patients with monophasic pattern, meaning that these patients have active disease before and immediately after diagnosis and after some time they achieve prolonged remission. Interestingly, about half of these patients do so and require no medications. On the other end of the clinical spectrum, approximately 50% of the patients demonstrate persistent disease activity and usually have the highest risk for developing co-morbidities and irreversible damage. The objective of this study is to define distinct phenotypes of lupus based on disease course.

 

Contact Information

For questions about this funding opportunity, application instructions or peer review process, please contact:

Leanne Mielczarek
Manager, National Operations
Lupus Canada
leanne.mielczarek@lupuscanada.org
1-800-661-1468